CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Shah and Dr. Wang on CAR T-Cell Therapy–Associated Toxicities in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the main CAR T-cell therapy–associated toxicities in hematologic malignancies.

FDA Grants RMAT Designation to CTX110 for Relapsed/Refractory CD19+ B-Cell Malignancies

November 23rd 2021

he FDA has granted a Regenerative Medicine Advanced Therapy designation to the allogeneic CAR T-cell therapy CTX110 for the treatment of patients with relapsed or refractory, CD19-positive B-cell malignancies.

Dr. Reiss Binder on Initial Results of a Phase 1 Study of CT-0508 in HER2+ Solid Tumors

November 23rd 2021

Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

Efforts Needed to Evaluate How CAR T-Cell Therapy Recipients Respond to COVID-19 Vaccination

November 22nd 2021

Muhammad Bilal Abid, MD, discusses immune-compromising factors that are indigenous to CAR T-cell recipients, the immunogenic potential of different COVID-19 vaccines, determinants of response, and the potential need for booster strategies.

Celularity and Imugene Enter into Potentially ‘Game-Changing’ Collaboration

November 18th 2021

Chimeric antigen receptor T-cell therapies are rapidly shifting the treatment paradigm for a multitude of hematologic malignancies.

Therapeutic Frontiers for Relapsed/Refractory Multiple Myeloma Expand With CAR T and Bispecific Antibodies

November 5th 2021

CAR T-cell therapy and bispecific antibodies for T-cell redirection are 2 recent immune strategies developed in the treatment of multiple melanoma.

Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL

November 5th 2021

Significant progress with rapidly evolving therapies, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, has been made to extend the median overall survival and improve outcomes for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Bispecific Monoclonal Antibodies Lead Immune-Directed Therapies into the Future

November 4th 2021

Increases investigative efforts into bispecific monoclonal antibodies could lead to their availability to treat a broad range of hematologic and solid cancers. Their current use in practice is limited to non–small cell lung cancer, leukemia, and hemophilia.

FDA Extends Decision Date for Cilta-Cel BLA in Relapsed/Refractory Multiple Myeloma

November 2nd 2021

The FDA has extended the Prescription Drug User Fee Act target date for the biologics license application seeking the approval of the CAR T-cell therapy ciltacabtagene autoleucel for use in adult patients with relapsed and/or refractory multiple myeloma.

FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

November 1st 2021

Dr. Shah discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia, key findings from the pivotal ZUMA-3 trial, and next steps with CAR T-cell therapy in the field.

COVID-19 Vaccination Strategies Should Consider Infection Risks for CAR T-Cell Therapy Recipients

October 28th 2021

Although CAR T-cell therapies have demonstrated unprecedented activity in patients with heavily pretreated relapsed/refractory hematologic malignancies, they are marked by a significant risk of infections and may limit the efficacy of COVID-19 vaccines.

Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

October 21st 2021

Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses, and the potential need for booster vaccine dosing in this population.

Miami Cancer Institute’s HIV/Cancer Clinic Utilizes Multidisciplinary Care to Improve Outcomes

October 15th 2021

Marco Ruiz, MD, discusses the new HIV/Cancer Clinic and its goals, challenges faced with patients who have cancer and HIV infection, and clinical trial opportunities that strive to move the needle forward.

Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination

October 14th 2021

Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

CAR T-cell Therapy CTX110 Shows Early Promise for Relapsed/Refractory CD19+ B-cell Malignancies

October 13th 2021

The allogeneic CD19-targeted CAR T-cell therapy CTX110 was found to elicit encouraging responses with favorable tolerability in patients with relapsed or refractory B-cell malignancies, according to data from the phase 1 CARBON trial.

Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma

October 8th 2021

The FDA approval of the first chimeric antigen receptor T-cell therapy in March 2021 for the treatment of relapsed/refractory multiple myeloma represents a significant advance.

FDA Places Clinical Hold on Select Allogeneic CAR T Trials After Report of Chromosomal Abnormality

October 8th 2021

The FDA has placed a hold on clinical trials examining Allogene Therapeutics, Inc.’s allogeneic CAR T-cell therapies for patients with cancer, following a report of a chromosomal abnormality in ALLO-501A CAR T cells in a patient who received treatment in the phase 1/2 ALPHA2 study.

FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory B-ALL

October 1st 2021

The FDA has approved brexucabtagene autoleucel as a treatment for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

FDA Approval Sought for Axicabtagene Ciloleucel for Second-Line Relapsed/Refractory LBCL

October 1st 2021

A supplemental biologics license application has been submitted to the FDA to expand the current indication of the CAR T-cell therapy axicabtagene ciloleucel to include the second-line treatment of adult patients with relapsed/refractory large B-cell lymphoma.

Dual-Targeted CAR T-Cell Therapy Shows Intriguing Activity in Relapsed/Refractory B-Cell Malignancies

September 24th 2021

Treatment with CD19-22.BB.z-CAR, a bispecific CAR T-cell therapy targeting CD19 and CD22, elicited high response rates and was well tolerated in adult patients with relapsed/refractory, CD19-positive B-cell acute lymphoblastic leukemia and large B-cell lymphoma.